Mazzoglio y Nabar // Personas viviendo con VIH 19. Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Alprazolam-ritonavir interaction: implications for the product labeling. Clin Pharmacol Ther 2000;67(4):335-341. 20. Hahn K, Arendt G, Braun JS, et al. A placebo-controlled trial of gabapentin for painful HIV-associated sensory neuropathies. J Neurol 2004;251(10):1260-1266. 21. Hansen RA, Gartlehner G, Lohr KN, et al. Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder. Am Intern Med 2005;143(6):415-426. 22. Harvey BH, Meyer CL, Gallichio VS, Manji HK. Lithium salts in AIDS and AIDS-related dementia. Psychopharmacol Bull 2002;36(1):5-26. 23. Hellinger FJ, Encinosa WE. Inappropiate drug combinations among privately insured patients with HIV disease. Med Care 2005;43(9 Suppl.):III53-III62. 24. Hesse LM, von Moltke LL, Shader RI, Greenblatt DJ. Ritonavir, efavirenz and nelfinavir inhibit CYP2D6 activity in vitro: potential drug interactions with bupropion. Drug Metab Dispos 2001;29(2):100-102. 25. Hill L, Lee KC. Pharmacotherapy considerations in patients with HIV and psychiatric disorders: focus on antidepressants and antipsychotics. Ann Pharmacotherapy 2013;47:75-89. 26. Hogeland GB, Swindelis S, Mc Nabb JC, et al. Lopinavir/ritonavir reduces bupropion concentrations in healthy subjects. Clin Pharmacol Ther 2007;81(1):69-75 27. Horberg MA, et al. Effects of depression and selective serotonin reuptake inhibitor use on adherence to highly active antirretrovial therapy and on clinical outcomes in HIV-infected patients. J Acquir Immune Defic Syndr 2008;47(3):384-90. 28. Hugem PW, Burger DM, Brinkman K, et al. Carmabacepine-indinavir interaction causes antirretroviral therapy failure. Ann Pharmacother 2000;34:365-70. 29. Jann MW, Spratlin V, Momary K, et al. Lack of pharmacokinetic drug-drug interaction with venlafaxine extended-reléase/indinavir and desvenlafaxine extendes reléase. Eur J Clin Pharmacol 2012;68:715-21. 30. Jover F, Cuadrado JM, Andreu L, Merino J. Reversible coma caused by risperidone-ritonavir interaction. Clin Neuropharmacol 2002:25(5):251-253. 31. Kato Y, Fujii T, Mizoguchi N, et al. Potential interaction between ritonavir and carbamacepine. Pharmacotherapy 2000;20(7):851-854. 32. Kelly DV, Beique LC, Bowmer MI. Extrapyramidal sumptoms with ritonavir/indinavir plus risperidone. Ann Pharmacother 2002;36(5):827-830. 33. La Spina I, Porazzi D, Maggiolo F, et al. Gabapentin in painful HIV-related neuropathy: a report of 19 patients, preliminary observations. Eur J Neurol 2001;8(1):71-75. 34. Lera G, Zyrulnik J. Pilot study with clozapine in patients with HIV-associated psychosis and drug-induced parkinsonism. Mov Disord 1999;14(1):128-131. 35. Levin GM, Nelson LA, DeVane CL, et al. A pharmacokinetic drug-drug interaction study of venlafaxine and indinavir. Psychopharmacol Bull 2001;35(2):62-71. 36. Maggi JD, Halman MH. The effect of divalproex sodium on viral load: a retrospective review of HIV-positive patients with maniac síndrome. Can J Psychiatry 2001;46(4):359-362. 288
37. Mangano AMM. Marcadores genéticos pronósticos en la infección por el hiv-1. Acta bioquím. clín. latinoam. [online]. 2007; 41(4):467-481. 38. Mazzoglio y Nabar MJ, Muñiz MM, Mejías Delamano AA, Muñoz A, Magrath Guimet N. Inhibidores de captación de serotonina y metabolismo óseo en pacientes VIH+ con tratamiento antirretroviral. Vertex Rev. Arg. de Psiquiat. 2015, XXVI;202-210. 39. Merry C, Mulcahy F, Barry M, et al. Saquinavir interaction with midazolam: pharmacokinetic considerations when prescribing protease inhibitors for patients with HIV disease. AIDS 1997;11(2):268- 269. 40. Park J, Vousden M, Brittain C, et al. Dose-related reduction in bupropion plasma concentration by ritonavir. J Clin Pharmacology 2010;50(10):1180-7. 41. Park-Wyllie LY, Antoniou T. Concurrent use of bupropion with CYP2B6 inhibitors, nelfinavir, ritonavir and efavirenz: a case series. AIDS 2003;17(4):638-640. 42. Penzak SR, Hon YY, Lawhorn WD, et al. Influence of ritonavir on olanzapine pharmacokinetics in healthy volunteers. J Clin Psychopharmacol 2002;22(4):366-370. 43. Perez Martinez D, Siaz Diaz R, Toledo Heras M. Protease inhibitor-induced carbamacepine toxicity. Clinical Neuropharmacol 2000;34:465-70. 44. Rabkin JG, McElhiney MC, Rabkin R, Ferrando SJ. Modafinil treatment for fatigue in HIV+ patients: a pilot study. J Clin Psychiatry 2004;65(12):1688-1695. 45. Rabkin JG, Wagner GJ, Rabkin R. Fluoxetine treatment for depression in patients with HIV and AIDS: a randomized, placebo-controlled trial. Am J Psychiatry 1999;156(1):101-107. 46. Repetto MJ, Petito JM. Psychopharmacology in HIV patients. Psychopharmacology in HIV patients. Psychosomatic Med 2008;70:585-92. 47. Romanelli F, Pomeroy C. Concurrent use of antirretrovirals and anticonvulsivants in human inmunodeficiency virus (HIV) seropositive patients. Curr Pharm Des 2003;9(18):1433-1439. 48. Simpson DM, McArthur JC, Olney R, et al. Lamotrigine for HIV-associated painful sensory neuropathies: a placebo-controlled trial. Neurology 2003;60(9):1508-1514. 49. Thompson A, Silverman B, Dzeng L, Treisman G. Psychotropic medications and HIV. Clin Infect Dis 2006;42:1305-10. 50. Treisman Gj, Angelino AF, Hutton HE. Psychiatric issues in the management of patients with HIV infection. JAMA 2001;286(22):2857-2864. 51. Vitiello B, Burnam MA, Bing EG, et al. Use of psychiatry medications among HIV-infected patients en United States. Am J Psychiatry 2003;160:547-54 52. Wagner GJ, Rabkin R. Effects of dextroanphetamine on depression and fatigue in men with HIV: a double-blind, placebo-controlled trial. J Clin Psychiatry 2000;61(6):436-440. 53. Yun LW, Maravi M, Kobayashi JS,et al. Antidepressant treatment improves adherence to antirretroviral therapy among depressed HIV-infected patients. J Acquir Immune Defic Syndr 2005;38(4):432- 438. 54. Zirulnik JL. Actualización en el manejo de psicofármacos en pacientes VIH positivos. Vertex Rev. Arg. De Psiquiat. 2015, XXVI;217-223. 289
